Added to YB: 2026-09-29
Pitch date: 2026-09-24
TTRX [bearish]
Turn Therapeutics Inc.
+12.46%
current return
Author Info
No bio for this author
Company Info
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
Market Cap
$372.1M
Pitch Price
$13.24
Price Target
N/A
Dividend
N/A
EV/EBITDA
-43.25
P/E
-42.77
EV/Sales
N/A
Sector
Pharmaceuticals
Category
N/A
TTRX - Zero
TTRX (short): Turn Therapeutics is assigned a zero price target because GX-03 is a topical PHMB antiseptic marketed as a cytokine-modulating atopic-dermatitis therapy despite no presented evidence of direct cytokine targeting and weak antimicrobial precedent. Apparent efficacy rests on a small, imbalanced interim cohort and a post-hoc 25-patient subgroup. The decisive 120–135-patient Stage 2 readout could arrive in 1H27, while limited runway and a going-concern warning leave little room for failure.
Read full article (9 min)